GLP-1 Agonists Explained: Semaglutide, Tirzepatide, and Retatrutide
What GLP-1 Agonists Actually Are
TheGLP-1 agonist class has become the most discussed category in both pharmaceutical medicine and peptide research. Semaglutide, tirzepatide, and retatrutide dominate headlines, clinical trials, and researcher interest — but the underlying biology that makes them work is often poorly explained by the sources generating the most attention. This guide covers the mechanism clearly, the clinical data accurately, and the distinctions between compounds honestly.
GLP-1 stands for glucagon-like peptide-1, an incretin hormone naturally produced by L-cells in the small intestine after food intake. Endogenous GLP-1 has a half-life of approximately 2 minutes — it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). The pharmaceutical breakthrough was engineering synthetic analogs resistant to DPP-4 degradation, extending the half-life from minutes to days and enabling once-weekly dosing.
How GLP-1 Receptor Activation Works
GLP-1 receptor agonists bind and activate the GLP-1 receptor, a G-protein coupled receptor expressed across multiple organ systems. The metabolic effects are mediated through several distinct tissue targets, each contributing a different component of the overall therapeutic profile.
In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion from beta cells. The “glucose-dependent” qualifier is critical — unlike sulfonylureas or exogenous insulin, GLP-1 agonists only stimulate insulin release when blood glucose is elevated. This mechanism substantially reduces hypoglycemia risk compared to older glucose-lowering approaches. GLP-1 receptor activation also suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output (PubMed: GLP-1 receptor mechanism).
In the brain, GLP-1 receptors in the hypothalamus and brainstem mediate appetite suppression and satiety enhancement. The paraventricular nucleus and the nucleus tractus solitarius are key sites where GLP-1 signaling reduces food intake. This central appetite regulation — not the peripheral metabolic effects — accounts for most of the weight loss observed in clinical trials.
In the gastrointestinal tract, GLP-1 receptor activation slows gastric emptying, prolonging the time food remains in the stomach. This contributes to satiety (feeling full longer after meals) and moderates postprandial glucose excursions by slowing carbohydrate absorption. The gastric slowing also contributes to the nausea that is the most common side effect of GLP-1 agonists, particularly during dose titration.
Semaglutide: The First Blockbuster
Semaglutide was developed by Novo Nordisk and approved by the FDA as Ozempic (for type 2 diabetes, 2017) and Wegovy (for weight management, 2021). It is a selective GLP-1 receptor agonist — it activates only the GLP-1 receptor with no activity at GIP or glucagon receptors.
The STEP clinical trial program established semaglutide’s weight loss efficacy. STEP 1 demonstrated mean weight loss of 14.9% with semaglutide 2.4 mg weekly over 68 weeks in participants with obesity but without diabetes. STEP 2 showed 9.6% weight loss in participants with type 2 diabetes. The consistency across trials — spanning different populations, durations, and comparators — built the evidence base that transformed obesity treatment (PubMed: Semaglutide STEP trials).
The SELECT trial then demonstrated something unprecedented for a weight loss medication: a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in participants with established heart disease and overweight/obesity. This cardiovascular benefit, independent of the weight loss itself, expanded semaglutide’s clinical significance beyond metabolic endpoints.
Semaglutide achieves its long half-life (~7 days) through a C18 fatty diacid modification that promotes albumin binding, shielding the molecule from renal clearance and DPP-4 degradation. This engineering enables the once-weekly dosing that has been central to its commercial success and patient/researcher compliance.
Tirzepatide: The Dual Agonist
Tirzepatide, developed by Eli Lilly and approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023), introduced a fundamentally different pharmacological approach: simultaneous activation of both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.
GIP receptor activation adds mechanisms that GLP-1 alone does not provide. GIP signaling enhances insulin secretion through a distinct intracellular pathway, modulates adipose tissue metabolism (potentially influencing fat distribution between visceral and subcutaneous depots), and may contribute to brown fat activation and thermogenesis. The combined effect is not simply additive — research suggests synergistic interactions between the two receptor pathways.
The clinical data reflects this mechanistic difference. The SURPASS-2 trial directly compared tirzepatide against semaglutide 1 mg in participants with type 2 diabetes. Tirzepatide 15 mg produced significantly greater HbA1c reduction (2.46% vs 1.86%) and weight loss (12.4 kg vs 6.2 kg). The SURMOUNT-1 trial documented mean weight loss of 22.5% with tirzepatide 15 mg over 72 weeks in participants without diabetes — the highest weight loss percentage achieved by any approved medication.
Whether tirzepatide’s dual agonism produces cardiovascular benefits comparable to semaglutide’s proven MACE reduction remains an open question. The SURPASS-CVOT trial will provide definitive data.
Retatrutide: The Triple Agonist
Retatrutide, in development by Eli Lilly, adds a third receptor target: the glucagon receptor. This triple agonism (GLP-1 + GIP + glucagon) represents the current frontier of incretin-based research.
Glucagon receptor activation contributes mechanisms absent from both semaglutide and tirzepatide. Glucagon stimulates hepatic lipid oxidation and thermogenesis, potentially increasing energy expenditure beyond what appetite suppression alone achieves. This adds a “burn more” component to the “eat less” effect of GLP-1 agonism — a combination that theoretical modeling suggests should produce greater net energy deficit than either mechanism alone.
Phase 2 data for retatrutide showed mean weight loss of 24.2% at the highest dose over 48 weeks — and the weight loss curves had not plateaued at study end, suggesting the ultimate effect could be larger with continued treatment. This exceeds tirzepatide’s Phase 3 results over a shorter treatment period, though cross-trial comparisons carry inherent limitations (PubMed: Retatrutide Phase 2 data).
Retatrutide has not yet received FDA approval. Phase 3 trials (TRIUMPH program) are ongoing across multiple indications including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH/NAFLD). Results are expected in 2025-2026.
How These Compounds Compare
The progression from semaglutide to tirzepatide to retatrutide illustrates a clear pharmacological trend: each successive generation adds receptor targets, and each addition has corresponded to greater metabolic effects in clinical trials.
Semaglutide (1 receptor) → 14.9% weight loss. Tirzepatide (2 receptors) → 22.5%. Retatrutide (3 receptors) → 24.2% and still declining. Whether this pattern reflects the intrinsic superiority of multi-receptor agonism or differences in dosing, trial design, and patient populations is an active area of research debate.
Side effect profiles across all three compounds share a common GI signature — nausea, vomiting, diarrhea, constipation — driven by the shared GLP-1 receptor agonism. Dose titration over 4-20 weeks is standard practice to mitigate these effects. Whether tirzepatide’s GIP agonism or retatrutide’s glucagon agonism modify the GI tolerability profile relative to semaglutide alone is still being characterized in controlled trials.
Emerging compounds in the pipeline include survodutide (GLP-1/glucagon dual agonist without GIP), orforglipron (the first non-peptide oral GLP-1 agonist), amycretin (oral GLP-1/amylin dual agonist), and CagriSema (semaglutide + cagrilintide co-formulation). The field is evolving rapidly, and today’s frontier compounds will likely be joined by additional multi-target agents within 1-2 years (Wikipedia: GLP-1 receptor agonists).
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual agonism produced greater weight loss (22.5% vs 14.9%) and HbA1c reduction in clinical trials, though the compounds have not been compared at equivalent doses across all trials.
Is retatrutide approved by the FDA?
No. Retatrutide is in Phase 3 clinical trials (TRIUMPH program). Phase 2 data showed 24.2% weight loss at the highest dose over 48 weeks with curves still declining. FDA approval depends on Phase 3 results expected in 2025-2026.
Why do GLP-1 agonists cause nausea?
GLP-1 receptor activation slows gastric emptying, prolonging the time food remains in the stomach. This delayed gastric motility triggers nausea, particularly during early treatment or dose increases. The effect typically diminishes over weeks as the body adjusts, which is why all GLP-1 agonists use gradual dose titration schedules.
Are GLP-1 agonists peptides?
Semaglutide, tirzepatide, and retatrutide are all peptide-based compounds — modified versions of naturally occurring incretin hormones. However, newer agents like orforglipron are non-peptide small molecules that activate the same GLP-1 receptor, potentially enabling oral dosing without the bioavailability limitations that peptides face in the GI tract.
PeptideQuill provides independent research news and analysis. This content is for informational purposes only and does not constitute medical advice.
